Bone News and Research RSS Feed - Bone News and Research

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences. [More]
Very small changes in blood acidity level may have detrimental impact on patients with CKD

Very small changes in blood acidity level may have detrimental impact on patients with CKD

A University of Manchester scientist has discovered that very small changes in the level of acidity in blood may have a detrimental impact on the health of patients with kidney disease. [More]
Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS). [More]
BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm's phase 2a ALS study meets primary endpoint

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced positive final results from its phase 2a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS) patients, which enrolled 14 subjects at Hadassah Medical Center in Jerusalem. [More]
Low alcohol consumption, plant-based diet reduce risk of obesity-related cancers

Low alcohol consumption, plant-based diet reduce risk of obesity-related cancers

Low alcohol consumption and a plant-based diet, both healthy habits aligning with current cancer prevention guidelines, are associated with reducing the risk of obesity-related cancers, a New York University study shows. [More]
Amedica's CASCADE data shows silicon nitride spacers are comparable to hollow-body PEEK spacers

Amedica's CASCADE data shows silicon nitride spacers are comparable to hollow-body PEEK spacers

Amedica Corporation, a biomaterial company that develops and commercializes silicon nitride ceramics, today released the results of its CASCADE study, a blinded, randomized clinical trial that compared outcomes of spinal fusion surgery between its composite silicon nitride spacers manufactured with a central core of cancellous structured ceramic (CsC), to the gold standard, i.e., PEEK (polyether ether ketone plastic) spacers filled with bone autograft. [More]
Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia secures additional $10 million to support development of palovarotene for treatment of FOP

Clementia Pharmaceuticals, Inc. today announced that it has secured an additional $10 million from current investors to support development of the company's lead compound palovarotene for the treatment of fibrodysplasia ossificans progressive (FOP). [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
Three common health problems tied to oral health

Three common health problems tied to oral health

Many people think that going to the dentist is all about getting a bright and shining smile. While this is an important aspect of dentistry, an experienced dentist like Farzad Feiz, DDS, of Calabasas Dental Group and California Dental Care can also help patients with their overall health. [More]
Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

Radiation/chemotherapy increases risk of leukemia in early-stage breast cancer patients

The risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer remains very small, but it is twice as high as previously reported, according to results of a new study led by researchers at the Johns Hopkins Kimmel Cancer Center. [More]
Research shows modern humans have less bone density than earlier human ancestors

Research shows modern humans have less bone density than earlier human ancestors

New research shows that modern human skeletons evolved into their lightly built form only relatively recently — after the start of the Holocene about 12,000 years ago, and even more recently in some human populations. [More]
Injection technique provides pain relief following knee replacement surgery

Injection technique provides pain relief following knee replacement surgery

It's estimated that more than half of adults in the United States diagnosed with knee osteoarthritis will undergo knee replacement surgery. [More]
Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system. [More]
C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

C3BS enrols 240th patient in CHART-1 European trial of C-Cure for treatment of congestive heart failure

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the enrolment of the 240th patient in its CHART-1 European trial for C-Cure, the first and only stem cell therapeutic using guided stem cells for the treatment of congestive heart failure. [More]
Bio2 Technologies' CLM Bioactive Scaffold receives FDA clearance

Bio2 Technologies' CLM Bioactive Scaffold receives FDA clearance

Bio2 Technologies, Inc. (a privately held development stage company) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its CLM Bioactive Scaffold. [More]
Research findings may lead to new treatment strategies for Ewing sarcoma

Research findings may lead to new treatment strategies for Ewing sarcoma

The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes - both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. These findings by Massachusetts General Hospital investigators, published in the November issue of Cancer Cell, may lead to new therapies targeting these aberrant mechanisms. [More]
Joslin study could lead to improved anti-aging drugs

Joslin study could lead to improved anti-aging drugs

In a study published today by Nature, researchers at Joslin Diabetes Center used a microscopic worm (C. elegans) to identify a new path that could lead to drugs to slow aging and the chronic diseases that often accompany it--and might even lead to better cosmetics. [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
Novel marker may help doctors choose most effective treatment for older patients with AML

Novel marker may help doctors choose most effective treatment for older patients with AML

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML). [More]
Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Back pain is exceptionally common. In fact, to not experience back pain at some point of your life would be thoroughly abnormal. Experiencing back pain is like becoming tired or becoming sad; we don’t necessarily like it, but it’s perfectly common. [More]